BridgeBio Pharma Inc BBIO:NASDAQ

Last Price$39.35NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/06/21

Today's Change+0.73(1.89%)
Bid (Size)$39.35 (1)
Ask (Size)$40.85 (1)
Day Low / High$37.96 - 39.57
Volume585.1 K
 

View Biotechnology IndustryPeer Comparison as of 12/06/2021

 

BridgeBio Pharma Inc ( NASDAQ )

Price: $39.35
Change: +0.73 (1.89%)
Volume: 585.1 K
4:00PM ET 12/06/2021
 
 

Sanara Medtech Inc ( NASDAQ )

Price: $26.17
Change: -0.62 (2.31%)
Volume: 26.2 K
3:58PM ET 12/06/2021
 
 

TherapeuticsMD Inc ( NASDAQ )

Price: $0.38
Change: -0.08 (17.98%)
Volume: 9.9 K
4:00PM ET 12/06/2021
 
 

LifeVantage Corp ( NASDAQ )

Price: $6.43
Change: +0.28 (4.55%)
Volume: 38.7 K
4:00PM ET 12/06/2021
 
 

Cocrystal Pharma Inc ( NASDAQ )

Price: $0.70
Change: -0.02 (2.10%)
Volume: 100.00
4:00PM ET 12/06/2021
 

Read more news Recent News

BridgeBio Pharma, Helsinn Group Team Up to Jointly Develop, Market New Cancer Treatment
8:53AM ET 11/19/2021 MT Newswires

BridgeBio Pharma (BBIO) and Helsinn Group said Friday they launched a collaboration to jointly develop and commercialize a new inhibitor targeting several...

SVB Leerink Adjusts BridgeBio Pharma's Price Target to $66 from $68, Keeps Outperform Rating
8:45AM ET 11/19/2021 MT Newswires

BridgeBio Pharma (BBIO) has an average rating of buy and price targets ranging from $66 to $91, according to analysts polled by Capital IQ. (MT Newswires...

BridgeBio Pharma Q3 Net Loss Widens as Revenue Falls
9:03AM ET 11/04/2021 MT Newswires

BridgeBio Pharma (BBIO) reported a Q3 net loss Thursday of $1.06 per share, widening from a loss of $0.98 per share a year earlier. Analysts polled by...

-- Earnings Flash (BBIO) BRIDGEBIO Posts Q3 Revenue $2.3M
7:31AM ET 11/04/2021 MT Newswires

...

Company Profile

Business DescriptionBridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA. View company web site for more details
Address421 Kipling Street
Palo Alto, California 94301
Phone+1.650.391.9740
Number of Employees152
Chief Executive Officer & DirectorNeil Kumar
Chief Operating OfficerChristine E. Siu
Chief Financial Officer & SecretaryBrian C. Stephenson
Chief Scientific OfficerUma Sinha

Company Highlights

Price Open$38.55
Previous Close$39.35
52 Week Range$37.64 - 73.50
Market Capitalization$5.8 B
Shares Outstanding147.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.93
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-939.99%
Return on Equity138.59%

Analyst Ratings as of 10/22/2021

Buy
9
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset